Læknablaðið : fylgirit - 01.05.1978, Qupperneq 21

Læknablaðið : fylgirit - 01.05.1978, Qupperneq 21
Heinola Study Group FOLLOW-UP STUDY OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH GOLD, CHLOROQUINE, OR COMBINED GOLD AND STEROID Since many years gold and chloroquine have been important drugs in the treatment of rheuma- toid arthritis. Comparison between these has been rather infrequent. Corticosteroids have been , used in the rheumatoid arthritis generally as an additional drug in more severe cases. There has been some doubt about weakening of results of gold treatment, if gold and steroid are given at the same time. Thus in this study gold, chloroquine, and combined gold and stersid were chosen for comparison. It is evident that these kind of drugs or perhaps any drugs cannot entirely heal patients with irreversible joint changes. On the other hand it is rather difficult to find fresh arthritis cases for this type of drug trial, because it is not often possible to confirm the diagnosis of rheumatoid arthritis before follow-up of several months or even years. This study has, however, been done with patients who have at a very early stage of disease undergone all available clinical, laboratory, and x-ray examinations to find out any other reason for arthritic symptoms than rheumatoid arthritis. The whole material, of which these patients are a sample, has been presented here by Isomaki. The treatment was started in six month's time after the appearing of joint symptoms. The drugs for the patients were chosen according to the date of birth, which is not perhaps the best way of randomization. A blind trial would, however, have been impossible. The evaluation was done after one year's treatment, and if the diagnosis turned out to be wrong, the patient was taken out of the trial material. The dosage of the drugs was conventional. Gold was given as sodiumaurothiomalate, known as Myocrisin, at weekly intervals about 15 times until a total dose of 800 mg was achieved, and 50 mg monthly was continued then.. The chloro- quine group got hydroxychloroquine about 5 mg per kilogram daily. Those patients with combined gold and steroid treatment had the same amount of gold as those with only gold and additionally prednisolone 5-10 mg every other day or daily, if required. All patients had sufficient amount of non-steroidal anti-inflamma- tory analgesics, usually salicylates. At this stage our study comprises 85 patients. Table 1 gives some information about them. The three treatment groups were of rather the same size. The treatment of the fourth group was discontinued because of complications. Gold was the reason for discontinuation also in the group with steroid. AU complications were mild and reversible: rashes, proteinuria and slight blood changes, one gastrointestinal irritation in the chloroquine group. AU patients met at least three of the American Rheumatism Association criteria for rheumatoid arthritis, most of them met five, and as I said; exclusion of other arthritic diseases was as efficient as possible. In age and titre of rheumatoid faetor there are some differences but they are not statistically significant. Before the beginning of the treatment three indexes based on the clinical examination were compUed. These figures, which are shown as mean values in the table 2, indicate the severity of the patient's disease. The indexes for joint tenderness and sweUing are the number of affected joints. However, the small joints, for instance pip-j oints, of one hand or foot are regarded as one joint. Functional disabUity was determined according to 20 tests performed to the patient. Some non-significant differences between the groups were found before the treat- ment. After one year the same evaluation was done again. All three treatment groups were defi- nitely better. The crosses are indicating signifi- cant improvement of the mean values at the five per cent level. However, when the groups were compared tö each other, there were no significant differences between any of the four groups. It has been said that chronic rheumatoid arthri- tis wUl seldom be healed completely. It was interesting to see, however, how many patients of this type of patient material became totaUy symptomless during the one year follow-up. In the table 3 you will find numbers of patients who had total remission, 25 patients out of 85 were without any joint symptoms or findings. In the two groups treated with gold the remission was most frequent, about 40 per cent. The differ- ences are not significant but the five per cent 19
Qupperneq 1
Qupperneq 2
Qupperneq 3
Qupperneq 4
Qupperneq 5
Qupperneq 6
Qupperneq 7
Qupperneq 8
Qupperneq 9
Qupperneq 10
Qupperneq 11
Qupperneq 12
Qupperneq 13
Qupperneq 14
Qupperneq 15
Qupperneq 16
Qupperneq 17
Qupperneq 18
Qupperneq 19
Qupperneq 20
Qupperneq 21
Qupperneq 22
Qupperneq 23
Qupperneq 24
Qupperneq 25
Qupperneq 26
Qupperneq 27
Qupperneq 28
Qupperneq 29
Qupperneq 30
Qupperneq 31
Qupperneq 32
Qupperneq 33
Qupperneq 34
Qupperneq 35
Qupperneq 36
Qupperneq 37
Qupperneq 38
Qupperneq 39
Qupperneq 40
Qupperneq 41
Qupperneq 42
Qupperneq 43
Qupperneq 44
Qupperneq 45
Qupperneq 46
Qupperneq 47
Qupperneq 48
Qupperneq 49
Qupperneq 50
Qupperneq 51
Qupperneq 52
Qupperneq 53
Qupperneq 54
Qupperneq 55
Qupperneq 56
Qupperneq 57
Qupperneq 58
Qupperneq 59
Qupperneq 60
Qupperneq 61
Qupperneq 62
Qupperneq 63
Qupperneq 64
Qupperneq 65
Qupperneq 66
Qupperneq 67
Qupperneq 68
Qupperneq 69
Qupperneq 70
Qupperneq 71
Qupperneq 72
Qupperneq 73
Qupperneq 74
Qupperneq 75
Qupperneq 76
Qupperneq 77
Qupperneq 78
Qupperneq 79
Qupperneq 80
Qupperneq 81
Qupperneq 82
Qupperneq 83
Qupperneq 84
Qupperneq 85
Qupperneq 86
Qupperneq 87
Qupperneq 88
Qupperneq 89
Qupperneq 90
Qupperneq 91
Qupperneq 92
Qupperneq 93
Qupperneq 94
Qupperneq 95
Qupperneq 96
Qupperneq 97
Qupperneq 98
Qupperneq 99
Qupperneq 100
Qupperneq 101
Qupperneq 102
Qupperneq 103
Qupperneq 104
Qupperneq 105
Qupperneq 106
Qupperneq 107
Qupperneq 108
Qupperneq 109
Qupperneq 110
Qupperneq 111
Qupperneq 112
Qupperneq 113
Qupperneq 114
Qupperneq 115
Qupperneq 116
Qupperneq 117
Qupperneq 118
Qupperneq 119
Qupperneq 120
Qupperneq 121
Qupperneq 122
Qupperneq 123
Qupperneq 124
Qupperneq 125
Qupperneq 126
Qupperneq 127
Qupperneq 128
Qupperneq 129
Qupperneq 130
Qupperneq 131
Qupperneq 132
Qupperneq 133
Qupperneq 134
Qupperneq 135
Qupperneq 136
Qupperneq 137
Qupperneq 138
Qupperneq 139
Qupperneq 140
Qupperneq 141
Qupperneq 142
Qupperneq 143
Qupperneq 144
Qupperneq 145
Qupperneq 146
Qupperneq 147
Qupperneq 148
Qupperneq 149
Qupperneq 150
Qupperneq 151
Qupperneq 152
Qupperneq 153
Qupperneq 154
Qupperneq 155
Qupperneq 156
Qupperneq 157
Qupperneq 158

x

Læknablaðið : fylgirit

Direct Links

Hvis du vil linke til denne avis/magasin, skal du bruge disse links:

Link til denne avis/magasin: Læknablaðið : fylgirit
https://timarit.is/publication/991

Link til dette eksemplar:

Link til denne side:

Link til denne artikel:

Venligst ikke link direkte til billeder eller PDfs på Timarit.is, da sådanne webadresser kan ændres uden advarsel. Brug venligst de angivne webadresser for at linke til sitet.